Fundraising Fox

Dementia Discovery Fund β€” Full Portfolio

20 tracked investments Β· listed companies and verified rows first

Cerevancecerevance.cominπ•βœ“ verified

Cerevance develops precision novel therapeutics for central nervous system disorders, particularly neurodegenerative diseases, using its proprietary NETSseq platform and machine learning to identify targets from an extensive collection of human brain tissue samples.

AI & Machine LearningBiotechDeep TechHealthtechMedical DevicesBoston, US

Craig Thompson(Chief Executive Officer)inSagar Vaidya(Chief Medical Officer)inCarrie Ann Cook(Chief Business Officer)Mark Carlton(Chief Scientific Officer)inOttavio V. Vitolo(Chief Medical Officer)in

Co-investorsForesite CapitalGV (Google Ventures)SV Life SciencesDementia DiscoveryLightstone VenturesSV Health Investors+2 more

cumulus-neurosciencecumulusneuro.cominβœ“ verified

NeuLogiq is a research platform for clinical trials that integrates tablet-based cognitive assessments, EEG monitoring, and real-world behavioral data to measure brain function changes.

AI & Machine LearningBiotechDigital HealthHealthtechMedical DevicesBelfast, GB

Brian Murphy(Co-Founder & CSO)inTina(CEO)

Co-investorsClarendon Fund Managers Ltd.LifeArc Ventures

Harness Therapeutics Ltdharnesstx.cominβœ“ verified

Harness Therapeutics develops disease-modifying precision therapies for hard-to-treat neurodegenerative diseases through controlled modulation of CNS targets.

BiotechHealthtech

Jan Thirkettle(CEO Director)in

Co-investorsEpidarex CapitalOno Venture Investment, Inc.SV Health Investors

Dualitas Therapeuticsdualitastx.cominJul 2025SEC filingmedium confidence

Dualitas Therapeutics develops bispecific antibody therapies that pair a proprietary proximity engager arm with an antibody against a therapeutic target, using its DualScreen discovery engine to identify synergistic target combinations.

BiotechDeep TechSouth San Francisco, US

Forbes Huang(Co-Founder, Chief Operating Officer & Chief Business Officer)inGreg Lazar(Co-Founder & Chief Scientific Officer)inRichard Murray(Executive Officer, Director)Karim Dabbagh(Chief Executive Officer, Board Member)in

BoardAlicia Levey(Director)Michael Ross(Director)

Board seatNeil WeirΒ· per SEC Form D Β· $66.6M raise Β· filed Nov 2025

Co-investorsQiming Venture PartnersSV Health InvestorsVersant VenturesAlexandriaQiming HealthcareQiming Venture Partners USA

Alchemab Therapeuticsalchemab.comin𝕏

Alchemab operates a platform that identifies novel drug targets and therapeutics by analyzing patient antibody repertoires using deep B cell sequencing and computational analysis of samples from disease-resilient individuals.

AI & Machine LearningBiotechDeep TechHealthtech

Jane Osbourn(Chief Executive Officer)

Co-investorsSV Health InvestorsDCVC BioRA CapitalLightstone VenturesOno Venture Investment, Inc.British Business Bank+2 more

Amphistaamphista.comin𝕏Dec 2022

Amphista Therapeutics develops next-generation targeted protein degradation (TPD) medicines using its proprietary Targeted Glue technology, which is engineered to selectively trigger the destruction of disease-causing proteins.

BiotechCambridge, GB

Louise Modis(Chief Executive Officer)inMartin Pass(Chief Development Officer)inGiles Brown(Executive VP Drug Discovery)in

Co-investorsAdvent Life SciencesNovartis Venture FundSV Health InvestorsEuropean Investment FundForbionGilde Healthcare+1 more

EndLyz Therapeuticsendlyz.comin

Endlyz develops small-molecule disease-modifying therapeutics targeting the ATP13A2 and ATP10B lysosomal transporters to restore endo-lysosomal function and counter neurodegeneration.

BiotechDeep TechBoston, US

Joanna Wolak(Executive Officer, Director)inJonathan Behr(Director)John Gustofson(Director)Damian Crowther(Director)Zaven Kaprielian(Executive Officer, Director)

BoardLaurence Barker(Director)

Co-investorsOxford Science Enterprises

LoQus23loqus23.cominNov 2021

LoQus23 Therapeutics is a drug discovery company developing treatments for triplet repeat expansion diseases such as Huntington's disease, focused on preclinical CNS and neuroscience research.

BiotechDeep TechCambridge, GB

David Reynolds(Co-founder & CEO)inCaroline Benn(Co-founder & CSO)in

Co-investorsNovartis Venture FundSV Health InvestorsForbion

Nitrase Therapeuticsnitrasetx.comin

Nitrase Therapeutics is a clinical-stage biopharmaceutical company using its NITROME platform to develop therapeutics based on nitrases, a class of enzymes it discovered that drive protein nitration.

BiotechHealthtechLongevity

Irene Griswold-Prenner(Founder & Chief Executive Officer)in

Co-investorsMission BiocapitalSofinnova PartnersMission Bay Capital

Nitrome Biosciences

BiotechJackson, US

Irene Griswold-Prenner(Executive Officer, Director)

BoardZach Hall(Director)Ephraim Heller(Director)William McDowell(Director)Regis Kelly(Director)

Co-investorsSV Health InvestorsSofinnova Partners

NRG Therapeuticsnrgtherapeutics.cominSep 2025 Β· $67M

NRG Therapeutics is a biotech company developing small-molecule drugs targeting the mitochondrial permeability transition pore (mPTP) for neurodegenerative diseases such as ALS and Parkinson's.

BiotechHealthtechLongevity

Neil Miller(CEO)inRichard Rutter(CSO)inGrant Hawthorne(COO)inClaus Sundgreen(Chief Medical Officer)inPaul Thompson(CDO)in

BoardJonathan Savidge(Independent Non Executive Chair)

Co-investorsCriteria Bio VenturesNovartis Venture FundSV Health InvestorsBritish Business BankM Ventures

Quralisquralis.comin𝕏Mar 2023

QurAlis develops precision therapies for amyotrophic lateral sclerosis (ALS) and related neurodegenerative diseases by targeting specific disease-causing genetic drivers and molecular mechanisms.

BiotechDeep TechMedical DevicesCambridge, US

Kevin Eggan(Co-founder)inRoet(Co-founder)Woolf(Co-founder)Kasper Roet(Director, Executive Officer, Promoter)inShafique Virani(Executive Officer)inJason Brown(Mr. Brown is the Chief Financial Officer of the Issuer.)in

Co-investorsDroia VenturesMC Healthcare VenturesMission BiocapitalMitsui Global InvestmentSanofi VenturesSV Health Investors+6 more

Ribometrixribometrix.com

BiotechGreenville, US

Kevin Weeks(Executive Officer, Director)Katherine Warner(Executive Officer)Joshua Resnick(Director)Michael Solomon(Director)John Gustofson(Director)

BoardMike Dial(Director)in

Co-investorsHatteras Venture PartnersIllumina VenturesM VenturesMC Healthcare VenturesPappas CapitalSV Health Investors+1 more

Sudo Biosudobio.com

Sudo Biosciences develops small molecule therapeutics for neurological and immune-mediated inflammatory conditions.

BiotechHealthtechMedical DevicesMenlo Park, US

Jim Bristol(Director)Daniel Estes(Director)Scott Byrd(Executive Officer, Director)

Co-investorsFrazier Life SciencesMonograph Capital PartnersSanofi VenturesSV Health InvestorsTPG

Therapeuticssvhealthinvestors.com

SV Health Investors is a global private equity and venture capital investment platform specializing in healthcare across biotechnology, medical devices, and healthcare growth equity.

BiotechHealthtechMedical DevicesBoston, US

Co-investorsDementia Discovery

Therini Biotherinibio.cominApr 2023 Β· $36M

Therini Bio is a biotechnology company developing fibrin-targeting therapeutics to treat neurological and ophthalmological diseases, leveraging scientific discoveries in neurovascular and neuroimmune mechanisms of disease.

BiotechDigital HealthHealthtechMedical DevicesSacramento, US

Katerina Akassoglou(Scientific Founder, Director of the Center for Neurovascular Brain Immunology and Professor of Neurology at UCSF and Gladstone Institutes)inKaterina Akassoglou, PhD(Scientific Founder)Leslie Schulze(Executive Officer)Tara Nickerson(Executive Officer, Director)in

BoardOlga Danilchanka(Director)Laia Crespo-Martin(Director)

Co-investorsMRL Ventures FundSanofi VenturesSV Health InvestorsAngelini VenturesMitsui Global InvestmentApollo Health Ventures+1 more

Violetvioletlabs.cominMay 2023 Β· $10.6M

Violet Labs builds software tools for engineers designing and building physical products across industries including aerospace, defense, robotics, and energy.

Data & InfrastructureDeveloper ToolsEnterprise SoftwareHardware

Lucy Hoag(Founder)in

Co-investorsFelicis VenturesMaC Venture CapitalV1 VCHopelabNorthwell HoldingsOno Venture Investment, Inc.+2 more

Violetviolet.org.auMay 2023 Β· $10.6M

Violet provides free, personalised support for Australian families navigating end-of-life care, combining human connection and technology to offer practical guidance, emotional support, and tools for important conversations.

Digital HealthFintechHealthtechImpact & Social GoodMental HealthHaymarket, AU

BoardKate Carnell(Chairperson)

Co-investorsTechstarsHopelabNorthwell HoldingsOno Venture Investment, Inc.The Venture CollectiveUTEC

Violetjoinviolet.cominMay 2023 Β· $10.6M

Violet provides healthcare organizations with data analytics and tools to measure and improve their ability to deliver person-centered care that considers patients' individual preferences, identities, and experiences.

Data & InfrastructureDigital HealthHealthtechNew York City, US

Gaurang Choksi(CEO and Founder)inScott Zaloom(Head of Operations)inDr. Kay Nikiforova(Head of Clinical & Research)inEliot Kristan(Head of Engineering)in

Co-investorsSeae VenturesSemperVirens Venture CapitalThe Venture CollectiveW Health Ventures Gp LlcHopelabNorthwell Holdings+2 more

Violetviolet.ioin𝕏May 2023 Β· $10.6M

Violet provides a unified API for commerce infrastructure that simplifies checkout, catalog management, and order processing for platforms and marketplaces serving multiple merchants.

B2B MarketplacesE-commerceSaaS

Brandon Schulz(Founder)in

Co-investorsSeaChangeHopelabNorthwell HoldingsOno Venture Investment, Inc.Red Sea VenturesSugar Capital+2 more

Rows marked β€œSEC filing” are inferred from directors named on the company's SEC Form D β€” public regulatory data, not a portfolio list published by the firm.